Cibinetide

Drug Profile

Cibinetide

Alternative Names: ARA-290

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Araim Pharmaceuticals
  • Developer Araim Pharmaceuticals; Karolinska Institute; Queens University Belfast
  • Class Analgesics; Anti-inflammatories; Antirheumatics; Peptides
  • Mechanism of Action Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sarcoidosis; Neuropathic pain; Transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Depressive disorders; Diabetic macular oedema; Diabetic neuropathies; Ischaemia; Neuropathic pain; Rheumatoid arthritis; Type 2 diabetes mellitus
  • Preclinical Retinal disorders; Transplant rejection
  • No development reported Radiation injuries

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Radiation-injuries in USA (IV, Infusion)
  • 08 May 2017 Efficacy data from a phase IIb trial in Neuropathic pain released by Araim Pharmaceuticals
  • 29 Apr 2017 Pharmacodynamics data from a preclinical trial in Transplant rejection presented at the 2017 American Transplant Congress (ATC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top